CHEK1 and ovarian carcinoma: Several ATR inhibitors such as berzosertib and camonsertib or CHK1 inhibitors (CHK1i) remain under clinical investigation for advanced solid tumors and ovarian carcinoma (e.g. NCT02627443, NCT04497116, NCT02808650)5.